RT Journal Article
T1 Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma.
A1 Mendez-Vidal, Maria Jose
A1 Molina, Aurea
A1 Anido, Urbano
A1 Chirivella, Isabel
A1 Etxaniz, Olatz
A1 Fernandez-Parra, Eva
A1 Guix, Marta
A1 Hernandez, Carolina
A1 Lambea, Julio
A1 Montesa, Alvaro
A1 Pinto, Alvaro
A1 Ros, Silverio
A1 Gallardo, Enrique
K1 Antineoplastic agents
K1 Carcinoma, renal cell
K1 Kidney neoplasms
K1 Pazopanib
K1 Protein kinase inhibitors
K1 Quality of life
K1 Área de Gestión Sanitaria Sur de Sevilla
AB Pazopanib is indicated in the first-line treatment of metastatic renal cell cancer (mRCC). The aim of this study was to review the efficacy, safety, and pharmacokinetics of pazopanib and see how these aspects are linked to clinical practice. A non-exhaustive systematic review was conducted according to the three topics. No publication restrictions were imposed and the selected languages were Spanish and English. After that, a summary of the main results and findings of the review was presented and discussed during three meetings (one for each topic) with 13 medical oncologists that usually treat mRCC. At these meetings, a questionnaire on the first-line use of pazopanib in clinical practice was also drawn up. After the meetings, the questionnaire was completed by 60 specialist medical oncologists in renal cancer. The efficacy and safety of pazopanib have been demonstrated in several clinical trials, and subsequently confirmed in studies in real-world clinical practice. In addition to its clinical benefit and good safety profile, quality of life results for pazopanib, which compare favorably to sunitinib, make it a good option in the first-line treatment of patients. Special populations have been included in studies conducted with pazopanib, and it is safe for use in elderly patients, poor functional status, kidney failure, and mild or moderate hepatic impairment, and in patients with concomitant cardiovascular disease. The results of the questionnaire have shown that pazopanib is perceived as an effective drug, in which quality of life (QoL) outcomes are valued above all. This paper offers a comprehensive and critical summary of efficacy, tolerability, and pharmacokinetics of pazopanib in the treatment of mRCC. Pazopanib is an effective treatment with an acceptable safety profile. Its QoL and tolerability results offer certain advantages when compared with other therapeutic alternatives, and its use appears to be safe in different patient profiles.
PB BioMed Central
YR 2018
FD 2018-10-29
LK http://hdl.handle.net/10668/13239
UL http://hdl.handle.net/10668/13239
LA en
NO Méndez-Vidal MJ, Molina Á, Anido U, Chirivella I, Etxaniz O, Fernández-Parra E, et al. Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma. BMC Pharmacol Toxicol. 2018 Nov 26;19(1):77
DS RISalud
RD Apr 7, 2025